Business Standard

Friday, December 20, 2024 | 07:22 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

DCGI nod to Phase-1 trials of 'antisera' with potential to treat Covid-19

The 'antisera' is yet to undergo human clinical trials to establish safety and efficacy

Coronavirus, covid, tests
Premium

The pre-print version of the study regarding the development of the equine antisera has been posted on the Research Square platform.

Press Trust of India New Delhi
The Drugs Controller General of India has given permission for conducting Phase-1 human clinical trial for an "antisera" that was developed by injecting inactivated SARS-CoV-2 in horses and can be a potential treatment for Covid-19, ICMR officials said on Tuesday. The 'antisera' has been developed by the Indian Council of Medical Research (ICMR) in collaboration with a Hyderabad-based bio-pharmaceutical firm. "With Biological E Limited we have developed an horse 'antisera' and we have just got clearance for conducting clinical trials for that," ICMR Director General Dr Balram Bhargava said at press briefing on Tuesday.

The 'antisera' is yet to undergo human

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in